InVivo Therapeutics Holdings Corp. (NVIV), a developer of
groundbreaking technologies for the treatment of spinal cord injuries
(SCI) and other neurotrauma conditions, today announced that CEO Frank
Reynolds is scheduled to appear live in New York City on Fox News
Channel’s “Tech Take” on Thursday, June 27th. “Tech Take” is
hosted by anchor Adam Housley and airs on Thursdays at 1:00pm ET.
InVivo Therapeutics has pioneered a treatment that uses a biocompatible
polymer-based scaffold to provide structural support to a damaged spinal
cord in order to spare tissue from scarring while improving recovery and
prognosis after traumatic SCI. Recently, the U.S. Food and Drug
Administration (FDA) granted two approvals to the Company, the first for
Humanitarian Use Device (HUD) designation, which the Company believes
will expedite the product’s path to market, and the second to approve
the Company to begin a first-in-man clinical trial of the technology. On
the show, Reynolds will discuss the product and the upcoming pilot
study, as well as the platform the Company has built for developing new
options for a wide range of conditions.
Adam Housley joined Fox News Channel in 2001 as a Los Angeles-based
correspondent. Recently, Housley covered the Japanese earthquake and
tsunami, reported in both English and Spanish during the Chilean Miners
rescue and, earlier in 2010, reported live from Haiti after the deadly
earthquake.
Fox News Channel airs locally on channel 841.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform
technology to develop treatments to improve function in individuals
paralyzed from traumatic spinal cord injuries. The company was founded
in 2005 based on proprietary technology co-invented by Robert S. Langer,
ScD. Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, MD, who is affiliated with Massachusetts General Hospital. In
2011, the company earned the prestigious David F. Apple Award from the
American Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. The publicly traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Certain statements contained in this press release that are not
historical facts may constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities and Exchange Act of 1934, and the Company intends that
such statements are subject to the safe harbor created thereby. These
statements include, but are not limited to, those relating to the
potential up-listing of our common stock to a national securities
exchange, and the impact of any such up-listing, such as increasing
liquidity an unlocking inherent value in our stock. These
forward-looking statements are based on current expectations, but are
subject to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties
relating to the Company’s ability to up-list to a national securities
exchange, as well as other factors are identified and described in more
detail in our Annual Report on Form 10-K for the year ended December 31,
2012 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as
of the date of this release. Subsequent events or circumstances
occurring after such date may render these statements incomplete or out
of date. The Company undertakes no obligation and expressly disclaims
any duty to update such statements.
Copyright Business Wire 2013